
lzf/iStock through Getty Photographs
- The U.S. FDA has accredited use of MediWound’s (NASDAQ:MDWD) burn remedy NexoBrid in pediatric sufferers as younger as newborns.
- NexoBrid (anacaulase) is meant for elimination of eschar — lifeless tissue that kinds over wholesome pores and skin — for sufferers with deep partial- and/or full-thickness thermal burns.
- Approval was based mostly on section 3 information from hospitalized pediatric sufferers, and pediatric information from different section III and section II trials performed throughout NexoBrid’s growth.